• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease
Conclusion In this study, 57% of N-ERD patients tolerated higher doses of aspirin under dupilumab therapy.
Source: European Respiratory Journal - March 16, 2023 Category: Respiratory Medicine Authors: Schneider, S., Poglitsch, K., Morgenstern, C., Quint, T., Gangl, K., Sinz, C., Bartosik, T., Campion, N. J., Liu, D. T., Landegger, L. D., Tu, A., Stanek, V., Rocha-Hasler, M., Bangert, C., Eckl-Dorna, J. Tags: Asthma and allergy Original Articles: Asthma and allergy Source Type: research

Efficacy and Safety of Anti-Interleukin-5 Therapies in Chronic Rhinosinusitis with Nasal Polyps: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Conclusion: This systematic review and meta-analysis identified that anti-IL-5 treatments significantly improved the size of nasal polyps, health-related quality of life, and sense of smell in moderate to severe CRSwNP, and they were safe and well tolerated.Int Arch Allergy Immunol
Source: International Archives of Allergy and Immunology - February 2, 2022 Category: Allergy & Immunology Source Type: research

Which Is the Best Biologic for Nasal Polyps: Dupilumab, Omalizumab, or Mepolizumab? A Network Meta-Analysis
Conclusion: This is the first NMA that compared different biologics in patients with CRSwNP. Based on the efficacy (NPS) and safety (AEs), dupilumab is the best choice and omalizumab is the second best option for CRSwNP. Although mepolizumab ranked second in efficacy, it had the highest risk of AEs.Int Arch Allergy Immunol
Source: International Archives of Allergy and Immunology - October 4, 2021 Category: Allergy & Immunology Source Type: research

Defining the Efficacy of Omalizumab in Nasal Polyposis: A POLYP 1 and POLYP 2 Subgroup Analysis
CONCLUSION: Together, these data suggest broad efficacy of omalizumab across clinical and patient-reported outcomes in patients with CRSwNP, independent of the underlying patient factors examined, including those with high eosinophil levels and those who have undergone previous surgery, which are associated with high recurrence.CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifiers: POLYP 1: ClinicalTrials.gov identifier NCT03280550 (https://clinicaltrials.gov/ct2/show/NCT03280550); POLYP 2: ClinicalTrials.gov identifier NCT03280537 (https://clinicaltrials.gov/ct2/show/NCT03280537).PMID:34382434 | DOI:10.1177/19458924211030486
Source: American Journal of Rhinology and Allergy - August 12, 2021 Category: ENT & OMF Authors: Cecelia Damask Meng Chen Cecile T J Holweg Bongin Yoo Lauren A Millette Christine Franzese Source Type: research

Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps
ConclusionDupilumab improved CRSwNP outcomes irrespective of surgery history, with greater improvements in endoscopic outcomes in patients with shorter duration since last surgery.
Source: International Forum of Allergy and Rhinology - February 21, 2021 Category: Allergy & Immunology Authors: Claire Hopkins, Martin Wagenmann, Claus Bachert, Martin Desrosiers, Joseph K. Han, Peter W. Hellings, Stella E. Lee, J érôme Msihid, Amr Radwan, Paul Rowe, Nikhil Amin, Yamo Deniz, Benjamin Ortiz, Leda P. Mannent, Rajesh Rout Tags: ORIGINAL ARTICLE Source Type: research

The effect of endoscopic olfactory cleft polyp removal on olfaction.
CONCLUSIONS: Evidence exists that olfactory cleft polyp surgery improves olfactory function outcomes. Long-term data beyond 6 months is needed to further validate these early promising outcomes. PMID: 26163252 [PubMed - in process]
Source: American Journal of Rhinology and Allergy - July 1, 2015 Category: ENT & OMF Authors: Kuperan AB, Lieberman SM, Jourdy DN, Al-Bar MH, Goldstein BJ, Casiano RR Tags: Am J Rhinol Allergy Source Type: research

Objective olfactory outcomes after revision endoscopic sinus surgery.
CONCLUSION: RESS resulted in objective evidence of olfactory improvement in approximately one-half of our cohort over 16 months of follow-up and offers a treatment option for an otherwise poor prognosis condition. PMID: 23883800 [PubMed - in process]
Source: American Journal of Rhinology and Allergy - July 1, 2013 Category: ENT & OMF Authors: Hsu CY, Wang YP, Shen PH, Weitzel EK, Lai JT, Wormald PJ Tags: Am J Rhinol Allergy Source Type: research